|

SPT-300 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Glyph Allopregnanolone, GlyphAllo, LYT-300

Pipeline

Phase 2: 1

Top Sponsors

  • Seaport Therapeutics1

Indications

  • Major Depressive Disorder With Anxious Distress1
  • Major Depressive Disorder (MDD)1
  • Depression1
  • Anxiety1

Chino, California1 trial

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

Seaport Investigator Site

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.